No Data
No Data
China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Jumps 21% This Week, Though Earnings Growth Is Still Tracking Behind Three-year Shareholder Returns
Zhongtai Securities: Short-term performance pressure in the traditional Chinese medicine sector, with main focus on improving quality and efficiency.
Against the backdrop of high base numbers in H1 2023, the traditional chinese medicine sector's performance is under short-term pressure. With the fading of the base effect and the arrival of the peak season in autumn and winter, the sector's performance is expected to gradually improve.
China Merchants Securities: Profit performance is better than revenue, and top OTC brands have stronger resilience.
In the first half of 2024, high-end scarce resources and traditional Chinese medicine OTC enterprises with brand and channel barriers performed well, while hospital-based traditional Chinese medicine enterprises were under short-term pressure due to industry policies and other factors.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Shares Lagging The Market But So Is The Business
CR Sanjiu's H1 Profit Jumps 28% on Higher Revenue
China Resources Sanjiu Medical & Pharmaceutical: Summary of Half-Year Report in 2024.
No Data
No Data